To investigate the efficacy and safety of programmed death protein 1 (PD-1) inhibitors in elderly patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.

The medical records of 103 patients with advanced NSCLC who received PD-1 inhibitors from January 1, 2020 to January 1, 2023 were retrospectively analyzed 103 patients with advanced NSCLC to compare the objective response rate (ORR), disease control rate (DCR), and adverse drug reaction (ADR) incidence rates among patients aged 65 to 74 years and those 75 years and older.

The ORR for the 65-74 age group (n=93) and ≥75 years group (n=10) was 44.09% and 40.00%, respectively. DCR was 83.87% and 90.00%, respectively. The overall incidence of ADR was 95.70% and 100.00%, and the incidence of grade ≥3 ADR was 18.28% and 20.00%. No statistically significant differences were observed between groups.

Elderly patients with advanced NSCLC receiving PD-1 inhibitors showed similar efficacy and safety between 65-74 years and ≥75 years. However, given the small sample size in the ≥75 years group, these preliminary results warrant further validation through large-scale, prospective studies.

To evaluate the effectiveness of clinical pharmacist intervention in standardizing the use of antiemetic drugs in tumor treatment by investigating the use of antiemetic drugs in inpatient medical records at a hospital.

Clinical pharmacists reviewed and analyzed the use of antiemetic drugs in the archived medical records of hospitalized patients who received intravenous antitumor treatment from January to April 2023. Following communication with physicians, intervention measures were implemented. The standardization rate and specific usage of antiemetic drugs were assessed at three months and six months post-intervention.

Before intervention, the standardization rate of antiemetic drugs at the hospital was 37.63%. The main issues contributing to non-standard use included inappropriate selection of antiemetic drugs, inappropriate drug selection, inadequate variety, insufficient treatment duration, and unreasonable upgrading of antiemetic regimens. After clinical Pharmacists' intervention, the standardized rate of antiemetic drugs was 63.53% (P<0.001) at three months post-intervention (the intervention group 1), and 86.36% (P<0.001) at six months post-intervention (the intervention group 2). Regarding specific antiemetic drugs, the usage rate of metoclopramide decreased significantly from 44.09% before intervention to 8.24% at three months and 7.95% at six months post-intervention (P<0.05). The usage of olanzapine showed a gradual increase, though the difference was not statistically significant.

Clinical pharmacists achieved significant improvements in the standardization of antiemetic drug use through targeted interventions, thereby reducing nausea and vomiting in tumor patients and achieving favorable intervention outcomes.

To establish a simple and economical high performance liquid chromatography (HPLC) method for determination of the concentrations of ceftazidime, meropenem, ceftriaxone and cefoperazone in human plasma.

The analysis was performed using an Agilent Extend C₁₈ (4.6 mm × 250 mm, 5 μm) chromatographic column, and protein components were removed using ultrafiltration tubes. A gradient elution system consisting of acetonitrile and 50 mmol·L^-1 sodium dihydrogen phosphate (pH 2.4) was employed as the mobile phase. The column temperature was maintained at 35 °C, with a flow rate of 1 mL·min^-1. Detection was achieved using a dual-wavelength ultraviolet spectrophotometry at 250 and 300 nm.

The four β-lactam antibiotics exhibited good linearity within their respective ranges (r²> 0.999), with an average extraction recovery ranging from 68.98% to 83.50%. The intra-day precision RSD was between 0.06% and 2.67%, while the inter-day precision RSD was between 0.04% and 3.32%.

This study successfully established an HPLC method for the determination of the concentrations of ceftazidime, meropenem, ceftriaxone, and cefoperazone, which is suitable for monitoring the plasma concentrations of these four β-lactam antibiotics.

To establish a size exclusion high-performance liquid chromatography (SEC-HPLC) method for the determination of the purity of recombinant human basic fibroblast growth factor (rh-bFGF).

The purity of rh-bFGF solution was determined using TSK G2000SWXL column and high-performance liquid chromatography, and the specificity, repeatability, precision, detection limit, stability, and durability of the method were evaluated.

The blank solvent has no interference with the rh-bFGF main peak, and the degradation impurities under various destruction conditions didn't interfere with the determination of the rh-bFGF peak, and the purity index of the rh-bFGF peak was greater than 990. The repeatability and intermediate precision experimental results showed that the separation degree of impurities and the rh-bFGF main peak was greater than 1.5, and the RSD was 0.36% and 0.64%, respectively. The detection limit was 0.185 μg·mL^-1. The durability experiment results show that fluctuations in flow rate, column temperature, and wavelength had no effect on the detection results, and the RSD of each condition was less than 2.0%.

The SEC-HPLC method developed has the advantages of simple operation, accurate results, strong specificity, high stability and good applicability, and can be used for rh-bFGF purity determination.

Through the analysis of a case of flagellate dermatitis caused by the use of bleomycin, to summarize and analyze the related skin toxicity of bleomycin, so as to provide reference for clinical rational drug use.

The treatment course of the patient was followed up, and the relevant literatures about flagellate dermatitis caused by bleomycin were searched and statistically analyzed by China National Knowledge Infrastructure, Wanfang, VIP, Google Scholar, Web of Science and PubMed.

The occurrence time of flagellate dermatitis caused by bleomycin in this case was 10 days after the first chemotherapy. Following admission, his condition showed gradual improvement following treatment with topical halomethasone ointment and freeze-dried human immunoglobulin for intravenous injection. A total of 52 articles on flagellate dermatitis caused by bleomycin were searched through the literature, including 25 males (47.2%) and 28 females (52.8%). The median time of occurrence was 25 days. The rash was mainly treated by local or systemic use of glucocorticoids. All patients' rashes improved.

Flagellate dermatitis is rare in clinic, but it is mostly mild to moderate. Doctors and clinical pharmacists should pay attention to the management of such adverse reactions and so as to improve the quality of life of patients.

To analyze the management and pharmaceutical care of a patient with Strongyloides Stercoralis mixed infection with multiple pathogens, thereby providing evidence for rational clinical prescribing.

Clinical pharmacists fully participated in the clinical treatment process of a patient with strongyloides stercoralis mixed infection with multiple pathogens, referring to the relevant clinical guidelines, they recommended to combine albendazole tablets for antiparasitic treatment, and to provide pharmaceutical monitoring and medication education to patients optimize anti-infective regimens and monitor adverse reactionss and adverse reactions monitoring.

In the treatment process, clinical pharmacists utilized their expertise to assist doctors in interpreting drug sensitivity and metagenomic next-generation sequencing (mNGS) reports, and carried out effective antiparasitic and anti-infection treatment. Suspected adverse drug reactions were treated in time, and the patient had a good prognosis.

Clinical pharmacists provide personalized pharmaceutical services for patients with mixed infections of multiple pathogens, and ensure the effectiveness and safety of medication.

To investigate the residue of mycotoxins in Fukang tablets.

The multi-in-one immunoaffinity columns were used to establish a UPLC-MS/MS quantitative analysis method, which was applied to analyze 29 batches of samples collected from six manufacturing enterprises.

The linear relationship of 11 mycotoxins was good within their respective linear ranges, with the correlation coefficient r ranging from 0.996 4 to 0.999 9 and the limit of quantitation (LOQ) ranging from 0.4 to 40 ng/tablet. The average recovery rate of 11 mycotoxins was 74.0% to 115.7%, and the RSD ranged from 2.6% to 11.3%. Among 29 batches of Fukang Tablets, except one batch in which fumonisin B3 (FB3) was measured at 10.4 ng/tablet, while the mycotoxin levels in the other samples were all less than 5 ng/tablet.

This method is rapid, accurate, highly sensitive, and reproducible, making it suitable for the quantitative detection and safety evaluation of multiple mycotoxins in Fukang tablets with complex matrix components.

To establish the quality standards for Jianpixiaoxian spray and provide a scientific basis for the optimization of its preparation process and quality control.

Jianpixiaoxian spray was prepared using a combination of steam distillation and water decoction methods. The quality of the product was preliminarily evaluated through pH value, filling volume variation, and spray volume. High-performance liquid chromatography (HPLC) was used to establish characteristic fingerprints for different batches, with neochlorogenic acid, chlorogenic acid, and 1, 3-dicaffeoylquinic acid used as marker components for multi-component content determination.

The prepared Jianpixiaoxian spray was a dark brown, clear, and transparent liquid with a fragrant aroma and a bitter taste. The pH value ranged from 6.2 to 7.4, with each bottle containing 9.5 to 10.5 mL and an average spray volume per actuation of 90.7 to 95.4 mg. The similarity of the HPLC fingerprints of 10 batches was above 0.90, with 13 common peaks identified. Among which Peaks 2, 4, and 8 were identified as neochlorogenic acid, chlorogenic acid, and 1, 3-dicaffeoylquinic acid, respectively. The contents of these three components were (0.314 7±0.0057) mg·mL^-1, (0.626 3±0.009 1) mg·mL^-1, and (0.170 9±0.003 2) mg·mL^-1.

The optimized preparation process for Jianpixiaoxian spray is feasible. The established HPLC fingerprint and multi-component content determination methods are specific, repeatable, and stable, providing an effective means for quality control and evaluation of this preparation and laying a foundation for its clinical application and industrial production.